Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Labopharm Once-Daily Tramadol NDA Planned For Second Half 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will conduct an additional pivotal trial in support of moderate to moderately-severe pain indication following discussions with FDA. Biovail’s once-daily tramadol Ralivia ER is pending at FDA with a PDUFA date of Oct. 31.

You may also be interested in...



Biovail’s Tramadol ER Approved Without Additional Clinical Studies

The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.

Biovail’s Tramadol ER Approved Without Additional Clinical Studies

The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.

Biovail Ralivia ER “Approvable” At FDA Pending Further Clinical Information

The company believes that the Ralivia ER NDA has sufficient data to fulfill FDA’s request. Biovail is seeking a U.S. marketing partner for the long-acting opioid analgesic.

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel